MedTrace Logo

Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients

NCT05841342 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 128

Last updated 2023-05-03

No results posted yet for this study

Summary

This prospective case-control study aims to evaluate the immune function and find PD-1 antibody efficacy predictors on Chronic Active Epstein-Barr Virus Infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis by detecting lymphocyte subsets proportions in peripheral blood mononuclear cells and the positive proportion of PD-1, PD-L1 and other indicators in each lymphocyte subsets in healthy people and patients using flow cytometry before and after the initial PD-1 therapy.

Conditions

  • Secondary Hemophagocytic Lymphohistiocytosis
  • Chronic Active Epstein-Barr Virus Infection

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Beijing Friendship Hospital

    lead OTHER

Eligibility

Min Age
2 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2024-04-30
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05841342 on ClinicalTrials.gov